Blog Archives

Diabetes: No end to SGLT2-inhibitor drugs side effects

01 September 2018 – The American Food and Drug Administration (FDA)  is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Read more ›

Tags: , , , , , , , , , , , , , , , , , , ,

Risk of leg and foot amputations under Canagliflozin (Invokana, Invokamet)

May 17, 2017 – Following up on an earlier Drug Safety Communication from May 2016 and based on new data from two large clinical trials, the American Food & Drug Administration (FDA) has concluded that the type 2 diabetes medicines Canagliflozin (Invokana), Canagliflozin/Metformin (Invokamet),  and Canagliflozin/Metformin (Invokamet XR) cause an increased risk of leg and foot amputations.

Read more ›

Tags: , , , , , , , ,

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in Type-2 Diabetes: Risk of acute kidney injury

June 16, 2016 – The sodium-glucose cotransporter 2 (SGLT2) is a protein that is encoded by the SLC5A2 gene. SGLT2 is one member of a larger family of sodium-glucose cotransporters which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. 

Read more ›

Tags: , , , , , , , , , , , , ,

SGLT2 inhibitors and diabetic ketoacidosis: PRAC makes recommendations to minimise risk to patients

February 14, 2016 – Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have been atypical,

Read more ›

Tags: , , , , , , , , , , , , , ,

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels

December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections.

Read more ›

Tags: , , , , , , , , , , , , , ,

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone fractures, and added new information about decreased bone mineral density in afflicted patients.

Read more ›

Tags: , , , , , , , ,

Medicines based on SGLT2 inhibiton may result in ketoacidosis, a serious condition of too much acid in the blood

May 15, 2015 – The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines Canagliflozin (Invokana), Dapagliflozin (Farxiga), and Empagliflozin (Jardiance) may lead to ketoacidosis,

Read more ›

Tags: , , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Gene that protects against osteoarthritis identified December 2, 2020
    Osteoarthritis is one of the most common problems associated with aging, and although there are therapies to treat the pain that results from the breakdown of the cartilage that cushions joints, there are no available therapies to modify the course of the disease.
  • Treating brain diseases now possible December 1, 2020
    Neurological diseases of the brain such as dementia, autism and schizophrenia are now a growing social problem. Nevertheless, studies on their definitive cause are still insufficient. Recently, a POSTECH research team has identified the mechanism in which such neurological diseases occur, thus solving the enigma to treating them.
  • Scientists identify new genetic MND risk factor in junk DNA December 1, 2020
    A new genetic risk factor for Motor Neurone Disease (MND), which if treated could halt or prevent the degenerative condition, has been identified in so-called 'junk DNA' by scientists at the University of Sheffield. The newly discovered genetic changes are present in up to one percent of MND patients.
  • Genomic analysis of mako shark reveals genes relating to tumor suppression in humans December 1, 2020
    Anecdotal reports claim that the incidence of cancer in sharks is very low, but there is not enough data to confirm this estimate categorically. A study published in the journal Genomics, however, presents strong evidence of anti-tumor activity in the genome of the Shortfin mako shark, Isurus oxyrinchus.
  • A large-scale tool to investigate the function of autism spectrum disorder genes November 30, 2020
    Scientists at Harvard University, the Broad Institute of MIT and Harvard, and MIT have developed a technology to investigate the function of many different genes in many different cell types at once, in a living organism. They applied the large-scale method to study dozens of genes that are associated with autism spectrum disorder, identifying how […]
Top